Marcaine (Bupivacaine Hydrochloride, Anhydrous)

Bupivacaine hydrochloride blocks voltage‑gated sodium channels on neuronal membranes, preventing sodium influx that is necessary for depolarisation. By inhibiting the generation and propagation of action potentials, it stops nerve signal transmission, resulting in reversible loss of sensation in the area where it is administered.

The dose of Marcaine is determined by the prescribing clinician based on the type of procedure, patient weight, age, and overall health status. Dosing is individualized and may vary widely; therefore, only a qualified healthcare professional should set the appropriate amount.

Safety data for Marcaine in pregnancy and lactation are limited, and it is classified as having an unknown pregnancy category. It should only be used when the potential benefit justifies any possible risk to the fetus or infant, and the decision must be made by a qualified obstetrician.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required) and necessary import documentation.

Marcaine (bupivacaine) has a longer duration of action and higher potency than lidocaine, making it suitable for procedures that require prolonged anesthesia. However, its onset is slower, and it carries a higher risk of cardiotoxicity, so clinicians balance these factors when selecting the appropriate agent.

Marcaine should be stored at 2‑8 °C in a refrigerator, protected from light, and must not be frozen or shaken. The container should remain sealed until use, and any solution that appears discoloured or cloudy should be discarded.

Marcaine is administered by infiltration injection directly into the tissue surrounding the nerves that supply the surgical or procedural area. The injection is performed by a trained healthcare professional using aseptic technique, and the volume injected is tailored to the specific clinical need.

The most serious risks include cardiovascular toxicity such as arrhythmias or cardiac arrest, severe hypotension, and central nervous system toxicity leading to seizures or respiratory depression. Immediate medical attention is required if any of these symptoms develop during or after administration.

Marcaine should be avoided in patients with known hypersensitivity to bupivacaine or other amide‑type local anesthetics, in individuals with severe cardiac conduction disorders, and in patients receiving concurrent high‑dose local anesthetics that could cause additive toxicity.